These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. [Clinical and animal experiment studies on the cell-cycle arrest using cytosine arabinoside in leukemias]. Büchner T; Barlogie B; Hiddemann W; Hofschröer J; Metz U; Ortheil NB; Kamanabroo D; Asseburg U Verh Dtsch Ges Inn Med; 1975; 81():1112-4. PubMed ID: 1065151 [No Abstract] [Full Text] [Related]
67. Combined effect of cytosine arabinoside and thiopurines. Valeriote F; Vietti T; Edelstein M Cancer Treat Rep; 1976 Dec; 60(12):1925-34. PubMed ID: 1026347 [TBL] [Abstract][Full Text] [Related]
68. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Hilton J Cancer Res; 1984 Nov; 44(11):5156-60. PubMed ID: 6488175 [TBL] [Abstract][Full Text] [Related]
69. Sequential administration of two oncostatic drugs: study of modalities for pharmacodynamic potentiation. Pouillart R; Huong TH; Brugerie E; Lheritier J Biomedicine; 1974 Dec; 21(12):471-9. PubMed ID: 4462870 [No Abstract] [Full Text] [Related]
70. Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside. Presant CA; Vietti TJ; Valeriote F; Coulter DM J Natl Cancer Inst; 1981 Dec; 67(6):1283-8. PubMed ID: 6171666 [TBL] [Abstract][Full Text] [Related]
71. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin. Edelstein M; Vietti T; Valeriote F Cancer Res; 1974 Feb; 34(2):293-7. PubMed ID: 4810905 [No Abstract] [Full Text] [Related]
72. Antigenicity of L1210 leukemic sublines induced by drugs. Nicolin A; Vadlamudi S; Goldin A Cancer Res; 1972 Apr; 32(4):653-7. PubMed ID: 5014777 [No Abstract] [Full Text] [Related]
73. Influence of continuous infusion of cytosine arabinoside on sequencing with daunorubicin in L1210 leukemia. Edelstein M; Valeriote F; Vietti T Cancer Treat Rep; 1978 Apr; 62(4):547-8. PubMed ID: 657151 [No Abstract] [Full Text] [Related]
75. Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213. Rivera G; Avery T; Roberts DW Eur J Cancer (1965); 1975 Sep; 11(9):639-47. PubMed ID: 1220978 [No Abstract] [Full Text] [Related]
76. Enhanced antitumor effect of cytosine arabinoside given in a schedule dictated by kinetic studies in vivo. Young RC; Goldberg D; Schein PS Biochem Pharmacol; 1973 Jan; 22(2):277-80. PubMed ID: 4763256 [No Abstract] [Full Text] [Related]
77. [Effect of chloramphenicol on the toxic and therapeutic actions of cyclophosphane]. Bogush TA Antibiot Med Biotekhnol; 1986 Mar; 31(3):199-202. PubMed ID: 3717919 [TBL] [Abstract][Full Text] [Related]
78. A dose-response study of resistance of leukemia L1210 to cyclophosphamide. DeWys WD J Natl Cancer Inst; 1973 Mar; 50(3):783-9. PubMed ID: 4708156 [No Abstract] [Full Text] [Related]
79. [Antileukemic activity of liposome forms of cytosine arabinoside and cyclocytidine]. Reshchikov VP; Afonin NI; Ermakov LN; Fertukova NM; Oksinoĭd OE Gematol Transfuziol; 1984; 29(5):49-51. PubMed ID: 6203808 [No Abstract] [Full Text] [Related]
80. Increased lifespan with altered sequence of administration of BCNU and cytoxan in L1210 leukemic mice. Straus MJ; Choi SC; Goldin A J Natl Cancer Inst; 1973 Feb; 50(2):475-80. PubMed ID: 4702118 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]